A flare of pre-existing erythema multiforme following BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine

Clin Exp Dermatol. 2021 Oct;46(7):1325-1327. doi: 10.1111/ced.14714. Epub 2021 May 25.

Authors

M J Lavery^{1 2}, S Nawimana¹, R Parslew^{1 2}, L Stewart¹

Affiliations

¹ Department of Dermatology, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
² Department of Dermatology, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, UK.

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Administration, Topical
BNT162 Vaccine
COVID-19 / diagnosis
COVID-19 / immunology
COVID-19 / prevention & control*
COVID-19 / virology
COVID-19 Vaccines / administration & dosage
COVID-19 Vaccines / adverse effects*
COVID-19 Vaccines / therapeutic use
Clobetasol / administration & dosage
Clobetasol / therapeutic use
Erythema Multiforme / chemically induced*
Erythema Multiforme / drug therapy
Erythema Multiforme / pathology
Female
Glucocorticoids / administration & dosage
Glucocorticoids / therapeutic use
Humans
Middle Aged
Preexisting Condition Coverage
SARS-CoV-2 / genetics
SARS-CoV-2 / immunology
Symptom Flare Up
Treatment Outcome

Substances

COVID-19 Vaccines
Glucocorticoids
Clobetasol
BNT162 Vaccine